Feb 13, 2026 08:00AM
Feb 2, 2026 08:01AM
Feb 2, 2026 08:00AM
Dec 18, 2025 04:05PM
Dec 18, 2025 04:05PM
Nov 6, 2025 04:15PM
Oct 9, 2025 08:00AM vTv Therapeutics adds four experts to scientific advisory board
Oct 9, 2025 08:00AM
Sep 2, 2025 08:00AM
Sep 2, 2025 08:00AM
Aug 11, 2025 08:00AM
Aug 7, 2025 08:00AM
Aug 7, 2025 08:00AM
May 15, 2025 12:00PM vTv Therapeutics (VTVT) Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes
May 15, 2025 12:00PM
Apr 9, 2025 06:03AM
Mar 20, 2025 05:35PM
Mar 17, 2025 08:30AM
Mar 17, 2025 08:30AM
Dec 9, 2024 07:33AM
Nov 12, 2024 04:05PM vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update
Aug 8, 2024 04:15PM
Jul 26, 2024 04:05PM
Jul 26, 2024 04:05PM
Jun 24, 2024 04:08PM
Jun 24, 2024 04:05PM
May 28, 2024 08:00AM
May 20, 2024 12:00PM CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER
May 9, 2024 04:51PM
Mar 19, 2024 08:30AM
Mar 13, 2024 08:00AM
Mar 4, 2024 08:00AM
Mar 4, 2024 08:00AM
Nov 2, 2023 08:05AM
Nov 2, 2023 08:00AM vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
Aug 11, 2023 04:31PM
Aug 11, 2023 04:30PM
Aug 10, 2023 08:33AM
Jun 16, 2023 08:03AM
Jun 16, 2023 08:00AM
Jun 15, 2023 07:33AM
Jun 1, 2023 10:37AM CANTEX PHARMACEUTICALS OBTAINS EXCLUSIVE WORLDWIDE RIGHTS TO INTELLECTUAL PROPERTY FROM GEORGETOWN UNIVERSITY FOR AZELIRAGON AS A POTENTIAL TREATMENT OF CANCER-RELATED COGNITIVE DECLINE
May 24, 2023 09:03AM
May 24, 2023 09:00AM
May 11, 2023 04:15PM
Mar 6, 2023 05:56PM
Mar 6, 2023 08:03AM
Mar 6, 2023 08:02AM
Feb 27, 2023 08:03AM Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma (VTVT)
Feb 27, 2023 08:02AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All